Magnesium Sulfate Effects on Onset and Duration of Low Dose Rocuronium in Patients Undergoing Laparoscopic Cholecystectomy
NCT ID: NCT02669368
Last Updated: 2016-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
75 participants
INTERVENTIONAL
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Magnesium Sulfate for TAP Analgesia During Laparoscopic Cholecystectomy
NCT02533284
Adding Magnesium Sulfate to Bupivacaine in Ultrasound Guided Paravertebral Block for Laparoscopic Cholecystectomy
NCT05099250
Efficacy of Esmolol Versus Magnesium Sulphate on Quality of Recovery in Patients Undergoing Laparoscopic Cholecystectomy: Randomized Controlled Study
NCT05850832
Effect of Nebulized Magnesium Sulfate on Post-intubation Stress Response in Patients Undergoing Laparoscopic Cholecystectomy
NCT07123714
Effect of Single Dose Intravenous Magnesium Sulfate on Postoperative Analgesic Consumption in Patients Undergoing Laparoscopic Cholecystectomy
NCT07328893
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard dose Rocuronium
Pretreatment of saline 100ml then giving Rocuronium 0.6 mg/kg at induction of anesthesia.
Saline
Patients in each group receive 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
Standard dose Rocuronium
0.6 mg/kg of Rocuronium given with induction of anesthesia
Low dose Rocuronium
Pretreatment of saline 100ml then giving Rocuronium 0.45 mg/kg at induction of anesthesia.
Saline
Patients in each group receive 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
Low dose Rocuronium
0.45 mg/kg of Rocuronium given with induction of anesthesia
Low dose Rocuronium + Magnesium Sulfate
Pretreatment of Magnesium sulfate 30 mg/kg then giving Rocuronium 0.45 mg/kg at induction of anesthesia.
Magnesium Sulfate
Patients in each group receive Magnesium sulfate 30 mg/kg in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
Low dose Rocuronium
0.45 mg/kg of Rocuronium given with induction of anesthesia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Magnesium Sulfate
Patients in each group receive Magnesium sulfate 30 mg/kg in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
Saline
Patients in each group receive 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
Standard dose Rocuronium
0.6 mg/kg of Rocuronium given with induction of anesthesia
Low dose Rocuronium
0.45 mg/kg of Rocuronium given with induction of anesthesia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI of 25-34.9 kg/m2.
* Patients scheduled for laparoscopic cholecystectomy.
Exclusion Criteria
* Hepatic or renal function impairment.
* Neuromuscular disease.
* Patients on medications affecting neuromuscular function.
* Patients with known allergy to the drugs.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Hamada Hamed
Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nawal Abdelaziz Gadelrab, Professor
Role: STUDY_CHAIR
Assiut University
Ola Mahmoud Wahba, Lecturer
Role: STUDY_DIRECTOR
Assiut University Hospitals
Ahmed Hamada Hamed Amin, Resident
Role: PRINCIPAL_INVESTIGATOR
Assiut University Hospitals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assiut University Hospitals
Asyut, Asyut Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01MgRo
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.